Bristol Myers Squibb’s Alzheimer’s Drug, BMS-986446, Granted FDA Fast Track Status

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is identified as a potentially undervalued stock for the next five years, particularly due to its advancements in Alzheimer's treatment [1] - The company's experimental drug, BMS-986446, has received Fast Track designation from the US FDA, which accelerates its review process [2][3] Drug Development - BMS-986446 is currently in Phase 2 testing for early-stage Alzheimer's patients and has shown significant efficacy in preclinical studies, including a sharp reduction in tau uptake and spread [2] - The drug targets the tau protein, aiming to neutralize its spread in the brains of Alzheimer's patients and potentially modify the disease's progression [3] Competitive Advantage - The Fast Track status provides Bristol-Myers Squibb with a competitive edge in the Alzheimer's treatment market, which is becoming increasingly crowded [2][3]